Julien Mazières

Also affiliated with Université Fédérale de Toulouse Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Hôpital Larrey, Institut Claudius Regaud

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer”.

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Nature Medicine(2022)10.1038/s41591-021-01655-5

N/A

0.975DataRank · unranked

665 citations

Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gérard Zalcman, S. Friard +38 more

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.09.009

N/A

0.104DataRank · unranked

1 citations

Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Geoffrey I. Shapiro +20 more

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

UNC Libraries(2020)10.17615/74ry-7003

N/A

0DataRank · unranked

0 citations

Editta Baldini, Pierre-Jean Souquet, Grace K. Dy, Ariel López-Chávez, Federico Cappuzzo +25 more

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of Oncology(2022)10.1016/j.annonc.2022.08.002

N/A

0DataRank · unranked

181 citations

Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

medRxiv(2022)10.1101/2022.02.17.22271120

N/A

0DataRank · unranked

1 citations

Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo‐Jack +24 more